SCHEMBL4090974

SCHEMBL4090974

O=C(O)CCNC(=O)c1ccc(C(Cc2ccccc2OC(F)(F)F)NC(=O)Nc2ccc3ccccc3c2)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.40
EPHX2 P34913 8/20 0.37
PIN1 Q13526 1/20 0.37
GCGR P47871 2/20 0.37
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FPR2 P25090 1/20 0.36
CYP1A2 P05177 1/20 0.36
RORC P51449 2/20 0.36
GCG P01275 1/20 0.35
EGLN2 Q96KS0 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
HSD17B13 Q7Z5P4 1/20 0.34
ADCY6 O43306 1/20 0.34
ADCY3 O60266 1/20 0.34
ADCY9 O60503 1/20 0.34
ADCY5 O95622 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4097815 0.87 GCGR (0.39) EPHX2GCGRFPR2RORCADCY6
SCHEMBL4086435 0.87 GCGR (0.40) EPHX2GCGRFPR2ADCY6ADCY3
SCHEMBL4095297 0.85 GCG (0.49) EPHX1GCGRGCGADCY6ADCY3
SCHEMBL6188310 0.83 FPR2 (0.43) EPHX1EPHX2PIN1GCGRFPR2
SCHEMBL4086649 0.80 GCGR (0.47) EPHX1GCGRMEN1NPC1RAB9A
SCHEMBL2663008 0.78 EPHX2 (0.41) EPHX2GCGR
SCHEMBL4091687 0.72 GCGR (0.47) EPHX2GCGRGCGADCY6ADCY3
SCHEMBL4091865 0.70 GCGR (0.49) EPHX2GCGRADCY6ADCY3ADCY9
SCHEMBL4095294 0.70 GCGR (0.51) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4085222 0.68 GCGR (0.45) EPHX2GCGRMEN1KMT2AFPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR EPHX1 2751/4885EPHX2 3463/4885PIN1 3527/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR EPHX1 2751/4885EPHX2 3463/4885PIN1 3527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.